(19)
(11) EP 2 424 527 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.07.2019 Bulletin 2019/29

(45) Mention of the grant of the patent:
10.04.2019 Bulletin 2019/15

(21) Application number: 09844195.9

(22) Date of filing: 28.07.2009
(51) International Patent Classification (IPC): 
A61K 31/353(2006.01)
A61K 31/4741(2006.01)
 A61K 45/06(2006.01)
A61K 31/519(2006.01)
(86) International application number:
PCT/US2009/051947
(87) International publication number:
WO 2010/126544 (04.11.2010 Gazette 2010/44)

(54)

MAST CELL STABILIZERS TO PREVENT OR TREAT LAMINITIS

MASTZELLENSTABILISATOREN ZUR PROPHYLAXE ODER BEHANDLUNG VON LAMINITIS

STABILISATEURS DE MASTOCYTES UTILISÉS POUR PRÉVENIR OU TRAITER LA FOURBURE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: 29.04.2009 US 387166

(43) Date of publication of application:
07.03.2012 Bulletin 2012/10

(73) Proprietor: Willowcroft Pharm Inc.
Newberry, FL 32669-2765 (US)

(72) Inventor:
  • OWEN, Charles, F.
    Littleton, CO 80162 (US)

(74) Representative: Mewburn Ellis LLP 
City Tower 40 Basinghall Street
London EC2V 5DE
London EC2V 5DE (GB)


(56) References cited: : 
WO-A1-2008/034740
US-A1- 2006 173 071
US-B2- 6 534 526
 US-A- 4 419 352
US-A1- 2009 304 648
   
     
    Remarks:
    The file contains technical information submitted after the application was filed and not included in this specification
     
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).